GL1X · GenesisL1 explorer

Research workbench

Crystal structure of DYRK1AA in complex with 10-bromo-substituted 11H- INDOLO[3,2-C]QUINOLONE-6-carboxylic acid inhibitor 5T

Analyse Crystal structure of DYRK1AA in complex with 10-bromo-substituted 11H… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4YLL
Type
protein
Length
342 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dual specificity tyrosine-phosphorylation-regulated kinase 1A
EC
2.7.12.1
UniProt
Q13627
Ligands
4E3, SO4
Pockets
3 · best druggability 0.62

Structure

x-ray diffraction · 1 distinct chain · 37% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADual specificity tyrosine-phosphorylation-regulated kinase 1A (EC 2.7.12.1)protein34237% helix, 18% strandQ13627

Ligands and binding sites

  • 4E3 · 10-bromo-2-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid · ligand · chains A
  • SO4 · Sulfate ion · ion · 5 copies · chains A
  • EDO · 1,2-ethanediol · additive · 9 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12520.620.81334E3
2740.450.8117empty
3540.340.7816empty

Modifications

Observed in the structure: 1 modified (phosphorylation).

Compared structures

  • 4YLL · Crystal structure of DYRK1AA in complex with 10-Bromo-substituted… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q13627 · AlphaFold monomer V2.0 prediction for dual specificity tyrosine… · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.